Treatment Options for Ulcerative Colitis

Overview of Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory condition that affects the large intestine, leading to inflammation and ulcers in the colon. The management of this inflammatory bowel disease can vary significantly among individuals, with treatment typically involving medications or surgery.

Role of Surgery in Treatment

Surgery is often considered a primary intervention for patients with ulcerative colitis, especially for those requiring hospitalization. However, there are concerns within the medical community regarding the potential adverse effects associated with surgical procedures and the use of medications.

Understanding Anti-TNF Therapy

Tumor necrosis factor (TNF) is a pro-inflammatory cytokine that contributes to increased inflammation in the colon and rectal regions. Anti-TNF biologic agents are used to disrupt the inflammatory process, targeting TNF to promote mucosal healing, induce and maintain remission, and decrease reliance on corticosteroids. Nonetheless, surgical procedures can impact these vital inflammatory mechanisms, affecting wound healing and the body’s ability to fend off infections.

Follow-Up Approach to Treatment

Top-Down Approach

The “top-down approach” emphasizes the early administration of anti-TNF medications, such as infliximab and adalimumab, to achieve remission in ulcerative colitis patients. Despite the rising use of anti-TNF therapy, the postoperative consequences have remained ambiguous.

Conflicts in Treatment

Patients who are candidates for anti-TNF therapy often face a high risk of requiring subsequent surgical interventions. This creates a conflict as the very treatments intended to manage the disease may lead to complications post-surgery.

Research on Anti-TNF Agents and Surgery

Study Overview

Researchers at Pennsylvania State University aimed to explore the effects of preoperative anti-TNF agents on surgical outcomes. This study, published in JAMA Surgery, focused on the relationship between the use of these medications and adverse outcomes after surgery.

Methodology

Utilizing a national claims database, the researchers identified 2,476 patients aged 18 and older diagnosed with ulcerative colitis. All participants had claims for various surgical procedures, including subtotal colectomy, total abdominal colectomy, total proctocolectomy with end ileostomy, or ileal pouch-anal anastomosis. The study examined postoperative complications, emergency department visits, and readmission rates within 90 days following surgery.

Key Findings

The study found no significant increase in complications for the colectomy or proctocolectomy groups. However, patients who underwent ileal pouch-anal anastomosis and had received anti-TNF agents within 90 days prior to surgery experienced a notable rise in postoperative complications.

Conclusion

This investigation highlights the implications of using anti-TNF therapy shortly before surgery, particularly for patients undergoing ileal pouch-anal anastomosis. These findings are crucial for guiding healthcare providers in making informed treatment decisions for patients with ulcerative colitis who may require surgical intervention.

Reference

Association of Preoperative Anti–Tumor Necrosis Factor Therapy With Adverse Postoperative Outcomes in Patients Undergoing Abdominal Surgery for Ulcerative Colitis, Audrey S. Kulaylat, MD; Afif N. Kulaylat, MD; Eric W. Schaefer, MS; Andrew Tinsley, MD; Emmanuelle Williams, MD; Walter Koltun, MD; Christopher S. Hollenbeak, PhD; Evangelos Messaris, MD, PhD, JAMA Surg. doi:10.1001/jamasurg.2017.1538 Published online June 14, 2017.